Filing Details

Accession Number:
0000899243-21-026780
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-30 18:00:34
Reporting Period:
2021-06-28
Accepted Time:
2021-06-30 18:00:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1745999 Beam Therapeutics Inc. BEAM Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1786322 Giuseppe Ciaramella C/O Beam Therapeutics Inc.,
26 Landsdowne Street
Cambridge MA 02139
President & Cso No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-06-28 78,580 $17.00 123,341 No 4 M Direct
Common Stock Disposition 2021-06-28 2,405 $103.83 120,936 No 4 S Direct
Common Stock Disposition 2021-06-28 5,464 $104.40 115,472 No 4 S Direct
Common Stock Disposition 2021-06-28 7,040 $105.52 108,432 No 4 S Direct
Common Stock Disposition 2021-06-28 10,444 $106.35 97,988 No 4 S Direct
Common Stock Disposition 2021-06-28 10,829 $107.30 87,159 No 4 S Direct
Common Stock Disposition 2021-06-28 30,369 $108.11 56,790 No 4 S Direct
Common Stock Disposition 2021-06-28 9,856 $109.32 46,934 No 4 S Direct
Common Stock Disposition 2021-06-28 2,173 $110.00 44,761 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-06-28 78,580 $0.00 78,580 $17.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
432,313 2030-02-05 No 4 M Direct
Footnotes
  1. The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.74 to $103.97, inclusive.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.04 to $104.96, inclusive.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.01 to $105.98, inclusive.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.00 to $106.97, inclusive.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.99, inclusive.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.00 to $108.90, inclusive.
  9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.00 to $109.95, inclusive.
  10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.01, inclusive.
  11. 25% of the shares subject to the stock option shall vest on the first anniversary of the vesting commencement date, February 5, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.